ArticleScientific reports2026
SARS CoV-2 seroprevalence and rising antibody titres across successive pandemic waves in accra, Ghana: August 2020 to January 2022.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shortly after its first outbreak in Wuhan, the SARS CoV-2 spread worldwide. This study determined SARS CoV-2 seroprevalence and compared anti-RBD IgG titre distributions among seropositive samples across four repeated cross-sectional surveys conducted during successive epidemic waves from August 2020 to January 2022. Age-specific seroprevalence and titre patterns were also examined across children, adolescents, and adults. We conducted a seroepidemiological cross-sectional study over four epidemic waves periods. A stratified 1,096 samples, reflecting the age and sex distribution of the Accra population, was selected from 15,000 residual clinical samples. Adjusted seroprevalence increased from 58.3% (95% CI: 53.9-62.6%) in wave 1 to > 90% by wave 2 and remained ≥ 96% in waves 3 and 4. Adults aged ≥ 20 years reached near-universal seropositivity earlier than children, who accumulated exposure more gradually. Despite this early plateau, geometric mean anti-RBD IgG concentrations increased from 162 BAU/mL in wave 1 to 625 BAU/mL in wave 3, stabilising at 584 BAU/mL in wave 4. Analyses of antibody titre distributions demonstrated that progressively larger proportions of adults showed concentrations substantially exceeding wave 1 baseline levels in later waves, indicating age-related differences in cumulative antigenic exposure. Across successive epidemic waves, Accra experienced intense and repeated SARS CoV-2 transmission, resulting in near-universal exposure of the adult population by May 2021. Children and adolescents showed a slower and more gradual increase in both seroprevalence and antibody concentrations. Anti-RBD IgG titres increased across successive waves and stabilised after August-November 2021, consistent with sustained cumulative antigenic exposure at the population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.